AMERICAN
FORK, Utah, May 1, 2024
/PRNewswire/ -- Biolexis Therapeutics, Inc. a clinical-stage
AI-driven biopharmaceutical company, today announced it will
present a late-breaking poster at the 2024 American Association of
Immunologists (AAI), taking place May 3-7,
2024, in Chicago, IL.
The conference brings together the top immunology experts for
in-depth discussions exploring a wide array of topics, highlighting
the latest groundbreaking discoveries in the field. Biolexis'
scientific team will be presenting pre-clinical data demonstrating
the efficacy of the company's novel PIM1-inhibitor, BLX-0631.
AAI poster presentation details are below:
Title: "Development of highly selective, potent,
orally available PIM1 inhibitor BLX-0631 shows a therapeutics
potential in Systemic Lupus Erythematosus (SLE)
models"
Session Title: Late-Breaking:
Therapeutic Approaches to Autoimmunity (PM)
Session Date and Time: Monday
May 6, 2024, 2:15 PM - 3:30
PM
Location: Exhibit Hall F1
Poster Board Number: B900
Abstract ID: 6301
More information can be found on the AAI meeting website.
About Biolexis Therapeutics, Inc.
Biolexis
Therapeutics is a privately held clinical-stage biopharmaceutical
company dedicated to developing small molecules targeting cancers,
metabolic, neurodegenerative, auto-immune, and inflammatory
diseases. Biolexis rapidly discovers and develops novel clinical
candidates with unprecedented speed and accuracy through their
proprietary MolecuLern™ AI-enabled drug discovery
process.
For more information, please visit www.biolexistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biolexis-therapeutics-to-present-late-breaking-poster-at-the-american-association-of-immunologists-aai-annual-meeting-2024-302133603.html
SOURCE Biolexis Therapeutics Inc